Scale-up Cealus Health starts key study on microbiome product
June 28, 2021Amsterdam UMC scale-up company Caelus Health has reached an important milestone.
Caelus Health recently started a key clinical trial in individuals suffering from Metabolic Syndrome or pre-diabetes; these individuals are at risk of developing Type 2 diabetes.
The microbiome product based on a single micro-organism (named A. soehngenii) may delay or even prevent the onset of diabetes. The trial is a final step in the development and registration of this product as a food supplement following successful completion of the previous study.
Caelus Health was established in close cooperation with Wageningen University.
More news
VU signs DNNL agreement to expand diversity, sustainability and entrepreneurship
“With this agreement, we fortify our collaboration, reaffirming our dedication to diversity, sustainability, and entrepreneurship – values exemplified by DNNL. An endeavor that aligns with the educational and research efforts we stand for as a university,” says VU President Jonkman.
News
Exciting launch of Social Sciences & Humanities Impact Fund at UvA
UvA Ventures Holding has launched the Social Sciences & Humanities (SSH) Impact Fund that aims to capitalize on SSH research by supporting the development of academic spin-offs that address societal challenges. The initiative is a response to the need for practical applications of SSH research, identified through discussions with university researchers. For whom? The SSH […]
News
Kepler Vision Technologies secures €1.5M investment to boost healthcare innovation
Kepler Vision Technologies, a spin-off company from the University of Amsterdam, secured a significant €1.5M investment from ROM InWest last month. The Dutch company will use the funds to accelerate the production of its ‘Kepler Night Nurse’ solution, a smart technology for care home fall detection. The company is now positioned for global expansion, targeting the UK and US markets.
News